A small percentage of Americans got the most recent covid-19 booster shot, and even fewer probably realize the federal government is preparing to recommend yet another shot as early as Tuesday.
Until a week or two ago, William Schaffner read that indifference as a sign the Centers for Disease Control and Prevention should advocate vaccinating only those most at risk from the virus.
But then Schaffner, an infectious disease specialist at Vanderbilt University Medical Center, changed his mind.
Members of the CDCโs Advisory Committee on Immunization Practices won him over to the argument that the vaccine be recommended for all Americans above 6 months of age, he said in an interview. The committee, which sets U.S. vaccination policy and helps determine insurance coverage for vaccines, will vote on the question Tuesday as it weighs the benefits of updated vaccines from Pfizer, Moderna, and Novavax.
Not all vaccine experts see it quite as Schaffner, a nonvoting liaison representative to the ACIP, does.
โI donโt plan to get it myself,โ said Paul Offit, 72, the director of the Vaccine Education Center at Childrenโs Hospital of Philadelphia. Heโs had two boosters and got covid last year. Another vaccine might increase his protection against mild infection for a few months, but like most Americansโ immune systems, his is already familiar enough with the virus to protect him from serious disease, Offit believes.
Some of Schaffnerโs scientific colleagues argue the government should be recommending the shot only for frail, older, sick, and immunocompromised people. Over 95% of the U.S. population are already covid-immunized through vaccination, infection, or both, and the risks of serious illness for healthy younger people are not great.
Schaffner doesnโt disagree. But lots of not-necessarily-vulnerable Americans do want the shot for themselves and their children, and, without a CDC recommendation, insurance companies wouldnโt have to pay for the vaccine.
Sign up for the Daily Dose Newsletter and get every morning’s best science news from around the web delivered straight to your inbox? It’s easy like Sunday morning.
Itโs โpretty awfulโ that Pfizer and Moderna, the two main covid vaccine producers, have decided to charge up to $130 a shot, compared with $30 last year for the booster, which was produced under government contract, said Kathryn Edwards, a professor of pediatrics at Vanderbilt and a member of an ACIP working group on covid. (Pfizer spokesperson Amy Rose said the price was โconsistent with the value deliveredโ and reflected higher expenses to provide the shots commercially.)
But a partial recommendation could leave the very groups who suffered most during the pandemic โ minorities and other disadvantaged groups โ unable to get vaccinated if they want but canโt afford to.
โThe last thing we need are financial barriers that would enhance disparities,โ Schaffner said.
A 1993 law requires the federal government to pay for childhood vaccines recommended by the ACIP, and more recent legislation requires coverage of adult vaccines within 15 days of an ACIP recommendation.
Pfizer and Moderna continue to make billions of dollars in sales of covid vaccines, although they are producing fewer doses. Moderna CEO Stรฉphane Bancel told investors in August that the company expected its global covid vaccine sales to be $6 billion to $8 billion this year, depending on uptake in the U.S. Pfizer expects about $14 billion this year.
Within a few years, both companies expect to be producing combination vaccines protecting against influenza, covid, and possibly respiratory syncytial virus. About 170 million flu vaccines were distributed last flu season in the U.S., so a combination product could lock in a large market for covid vaccines as well.
Despite broad recommendations for the updated covid booster shot released last fall, only 17% of the U.S. population got it โ and about 43% of those over 65. How many will get the vaccine this season is uncertain, as is the benefit of the shot. A study of the new Moderna vaccine showed that while it increased antibodies to various covid strains, it provided roughly the same protection against them as last yearโs booster shot, which was given again to the control group.
The new vaccine is โnot remotely a game changer,โ said John Moore, a professor of microbiology and immunology at Weill Cornell Medical College.
For healthier adults and children, โitโs a boost in protection for a few months,โ Moore said. Who exactly will benefit most is impossible to predict because the U.S. is โnot a cookie-cutter population.โ Its people have by now been exposed to a bewildering combination of vaccines, boosters, and different strains of the virus.
Christopher Ridley, a Moderna spokesperson, said the updated vaccine was well matched to current viral strains, adding, โWe encourage people to get vaccinated for covid when they get their annual flu shot.โ
Fearmongering has distorted the threat of the virus, Moore said. He is skeptical of the significance of the recent uptick in covid hospitalizations, and criticized social media posters who have raised fears about new viral strains that donโt seem to pose any fundamental challenge to the new vaccines.
โEditorial FOMO drove summer surge worries,โ Moore said, using an acronym for โfear of missing out.โ Despite worrying comments and tweets by physicians such as Eric Topol, director of the Scripps Research Translational Institute, about a new covid variant called BA.2.86, โit turned out to be a real nothingburger,โ Moore said.
Even Ashish Jha, who coordinated the Biden administrationโs covid response until returning to his post as dean of the Brown University School of Public Health this year, agrees there is some ambiguity in the issue. While he recommends that 20-year-olds get the booster, โa reasonable personโ could disagree.
Unfortunately, such discussions in the current environment are clouded by โnonsense and bad informationโ that causes confusion and hurts people, he said in a recent podcast interview.
Whether truly needed or not, the vaccines, proponents say, are safe enough that even the small benefit of taking them will outweigh the risks. The major, though rare, serious side effect of the Pfizer and Moderna vaccines โ myocarditis, which particularly affected men in their teens and 20s โ appears mainly to have occurred during the first two-shot series.
Paradoxically, those who most need protection from covid are often likely to have weakened immune systems that fail to generate the hoped-for response to vaccination.
So the vaccine is arguably most relevant for healthy people who come in frequent contact with vulnerable individuals. With that in mind, England has announced the new booster would be offered only to people who are 65 or older, in nursing homes, or immunologically vulnerable โ or who work or live with members of those groups.
โAny efforts to promote the new boosters should focus squarely on those at high risk,โ said Norman Hearst, a family physician in San Francisco. While recommending the vaccine for older patients, he said he wouldnโt advise a booster for young males because of the rare risk of myocarditis and the negligible benefit. โThe question is all the other people in between.โ
In a commentary last November, infectious disease doctors Shira Doron and Monica Gandhi said vaccination campaigns should be radically honest about the limited value of vaccines for long-term protection against infection. Such a campaign might advocate vaccinating children because even though it wonโt protect durably, โit might prevent the rare case of severe disease.โ
Meanwhile, the vaccine makers have their own plans for publicizing the vaccines. In its call with investors last month, Moderna said it was focused on increasing sales and solidifying Modernaโs market share with branded promotion. Its โawareness campaignsโ will tout ACIP recommendations and โconnect covid-19 with seasonal flu vaccines with the goal to drive consumers to get vaccinated this fall,โ a company official said.
Moderna is co-sponsoring tennisโ U.S. Open this year and aired a video at the event Sept. 8 honoring Arthur Ashe, the only Black man to win Grand Slam titles, whom it credited with helping destigmatize HIV by revealing he had the virus.
The video presentation suggested that Moderna, like Ashe, has done well by being bold.
This article was originally published in KFF Health News.
WORDS: Arthur Allenย (ArthurA@kff.org,ย @ArthurAllen202)
If you enjoy the content we create and would like to support us, please consider becoming a patron on Patreon! By joining our community, you’ll gain access to exclusive perks such as early access to our latest content, behind-the-scenes updates, and the ability to submit questions and suggest topics for us to cover. Your support will enable us to continue creating high-quality content and reach a wider audience.
Join us on Patreon today and let’s work together to create more amazing content! https://www.patreon.com/ScientificInquirer
Leave a Reply